Consultation: High-moderate risk changes to permissible ingredients - Vitamin B6 (pyridoxine hydrochloride, pyridoxal 5-phosphate, and pyridoxal 5-phosphate monohydrate)

While the consultation is open you can make a submission at our TGA consultation hub.

After the closing date, the submissions will be reviewed, and outcomes will be made available on the same page at the TGA consultation hub.

About this consultation

The Therapeutic Goods Administration (TGA) is seeking public comment on proposed changes to the Therapeutic Goods (Permissible Ingredients) Determination relating to listed medicines containing vitamin B6, namely pyridoxine hydrochloride, pyridoxal 5-phosphate and pyridoxal 5-phosphate monohydrate.

The High-moderate risk changes to permissible ingredients - Vitamin B6 (pyridoxine hydrochloride, pyridoxal 5-phosphate, and pyridoxal 5-phosphate monohydrate) consultation is available on the Consultation hub. The closing date for submissions is 25 November 2026.